
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1801407/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estimating the reproducibility of psychological science. Science, 2015, 349, aac4716.	12.6	4,926
2	Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nature Genetics, 2018, 50, 1112-1121.	21.4	1,835
3	Redefine statistical significance. Nature Human Behaviour, 2018, 2, 6-10.	12.0	1,763
4	Genome-wide association study identifies 74 loci associated with educational attainment. Nature, 2016, 533, 539-542.	27.8	1,204
5	Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value in Health, 2003, 6, 9-17.	0.3	948
6	Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nature Genetics, 2016, 48, 624-633.	21.4	870
7	Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015. Nature Human Behaviour, 2018, 2, 637-644.	12.0	845
8	Evaluating replicability of laboratory experiments in economics. Science, 2016, 351, 1433-1436.	12.6	789
9	GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment. Science, 2013, 340, 1467-1471.	12.6	750
10	Multi-trait analysis of genome-wide association summary statistics using MTAG. Nature Genetics, 2018, 50, 229-237.	21.4	700
11	Variability in the analysis of a single neuroimaging dataset by many teams. Nature, 2020, 582, 84-88.	27.8	634
12	Swedish population health-related quality of life results using the EQ-5D. Quality of Life Research, 2001, 10, 621-635.	3.1	539
13	Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nature Genetics, 2019, 51, 245-257.	21.4	536
14	Crowding Out in Blood Donation: Was Titmuss Right?. Journal of the European Economic Association, 2008, 6, 845-863.	3.5	525
15	Pride and Prejudice: The Human Side of Incentive Theory. American Economic Review, 2008, 98, 990-1008.	8.5	431
16	Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence. Nature Genetics, 2017, 49, 1107-1112.	21.4	425
17	Promises, Threats and Fairness. Economic Journal, 2004, 114, 397-420.	3.6	418
18	Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results. Advances in Methods and Practices in Psychological Science, 2018, 1, 337-356.	9.4	406

#	Article	IF	CITATIONS
19	Genetic Variation in Preferences for Giving and Risk Taking [*] . Quarterly Journal of Economics, 2009, 124, 809-842.	8.6	381
20	Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart Disease. New England Journal of Medicine, 1997, 336, 332-336.	27.0	372
21	Polygenic risk scores for schizophrenia and bipolar disorder predict creativity. Nature Neuroscience, 2015, 18, 953-955.	14.8	351
22	Gender differences in deception. Economics Letters, 2008, 99, 197-199.	1.9	333
23	Heritability of cooperative behavior in the trust game. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3721-3726.	7.1	324
24	The relationship between happiness, health, and socio-economic factors: results based on Swedish microdata. Journal of Socio-Economics, 2001, 30, 553-557.	1.0	306
25	Genome-wide analysis identifies 12 loci influencing human reproductive behavior. Nature Genetics, 2016, 48, 1462-1472.	21.4	284
26	The aversion to lying. Journal of Economic Behavior and Organization, 2009, 70, 81-92.	2.0	283
27	Eliciting Willingness to Pay Without Bias: Evidence from a Field Experiment. Economic Journal, 2008, 118, 114-137.	3.6	273
28	The Swedish Twin Registry: Establishment of a Biobank and Other Recent Developments. Twin Research and Human Genetics, 2013, 16, 317-329.	0.6	267
29	On the decision rules of cost-effectiveness analysis. Journal of Health Economics, 1993, 12, 459-467.	2.7	247
30	Swedish experience-based value sets for EQ-5D health states. Quality of Life Research, 2014, 23, 431-442.	3.1	246
31	Common genetic variants associated with cognitive performance identified using the proxy-phenotype method. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13790-13794.	7.1	244
32	Genetic Variation in Financial Decisionâ€Making. Journal of Finance, 2010, 65, 1725-1754.	5.1	235
33	The genetic architecture of economic and political preferences. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8026-8031.	7.1	225
34	Most Reported Genetic Associations With General Intelligence Are Probably False Positives. Psychological Science, 2012, 23, 1314-1323.	3.3	221
35	Testing guilt aversion. Games and Economic Behavior, 2010, 68, 95-107.	0.8	219
36	Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. Nature Genetics, 2022, 54, 437-449.	21.4	215

#	Article	IF	CITATIONS
37	Using prediction markets to estimate the reproducibility of scientific research. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15343-15347.	7.1	206
38	Heritability of ultimatum game responder behavior. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15631-15634.	7.1	204
39	Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy, 2001, 55, 51-69.	3.0	200
40	Intuition and cooperation reconsidered. Nature, 2013, 498, E1-E2.	27.8	200
41	Health-related Quality of Life in Patients with Psoriasis and Atopic Dermatitis Measured with SF-36, DLQI and a Subjective Measure of Disease Activity. Acta Dermato-Venereologica, 2000, 80, 430-434.	1.3	199
42	Interpretation of change scores in ordinal clinical scales and health status measures: The whole may not equal the sum of the parts. Journal of Clinical Epidemiology, 1996, 49, 711-717.	5.0	193
43	Social framing effects: Preferences or beliefs?. Games and Economic Behavior, 2012, 76, 117-130.	0.8	192
44	Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Quality of Life Research, 2011, 20, 309-320.	3.1	188
45	A note on the effect of unemployment on mortality. Journal of Health Economics, 2003, 22, 505-518.	2.7	184
46	Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. British Journal of Dermatology, 1999, 141, 1067-1075.	1.5	180
47	Assessing the Robustness of Power Posing. Psychological Science, 2015, 26, 653-656.	3.3	178
48	Economic evaluation in health care: Is there a role for cost-benefit analysis?. Health Policy, 1991, 17, 1-23.	3.0	175
49	Directional dominance on stature and cognition inÂdiverse human populations. Nature, 2015, 523, 459-462.	27.8	173
50	Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. Journal of Health Economics, 2001, 20, 441-457.	2.7	170
51	Genetic Influences on Political Ideologies: Twin Analyses of 19 Measures of Political Ideologies from Five Democracies and Genome-Wide Findings from Three Populations. Behavior Genetics, 2014, 44, 282-294.	2.1	169
52	Willingness to pay for antihypertensive therapy — results of a Swedish pilot study. Journal of Health Economics, 1991, 10, 461-473.	2.7	168
53	The Promises and Pitfalls of Genoeconomics. Annual Review of Economics, 2012, 4, 627-662.	5.5	168
54	The Decision Rules of Cost-Effectiveness Analysis. Pharmacoeconomics, 1996, 9, 113-120.	3.3	165

#	Article	IF	CITATIONS
55	A randomized trial of the effect of estrogen and testosterone on economic behavior. Proceedings of the United States of America, 2009, 106, 6535-6538.	7.1	164
56	The Willingness to Pay for In Vitro Fertilization: A Pilot Study Using Contingent Valuation. Medical Care, 1994, 32, 686-699.	2.4	163
57	Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83.	12.6	163
58	Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal, 1996, 17, 1001-1007.	2.2	160
59	Paying Respect. Journal of Economic Perspectives, 2007, 21, 135-149.	5.9	158
60	An experimental comparison of dichotomous choice contingent valuation questions and real purchase decisions. Applied Economics, 1998, 30, 643-647.	2.2	150
61	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	148
62	The friction cost method: A comment. Journal of Health Economics, 1997, 16, 249-255.	2.7	147
63	Do people care about social context? Framing effects in dictator games. Experimental Economics, 2013, 16, 349-371.	2.1	147
64	Standard gamble, time trade-off and rating scale: Experimental results on the ranking properties of QALYs. Journal of Health Economics, 1997, 16, 155-175.	2.7	139
65	A Note on Confidence Intervals in Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care, 1998, 14, 467-471.	0.5	135
66	Registered Replication Report: Rand, Greene, and Nowak (2012). Perspectives on Psychological Science, 2017, 12, 527-542.	9.0	129
67	Comparing meta-analyses and preregistered multiple-laboratory replication projects. Nature Human Behaviour, 2020, 4, 423-434.	12.0	129
68	ls generosity involuntary?. Economics Letters, 2007, 94, 32-37.	1.9	125
69	Business cycles and mortality: results from Swedish microdata. Social Science and Medicine, 2005, 60, 205-218.	3.8	123
70	Subjective Well-Being and Its Association with Subjective Health Status, Age, Sex, Region, and Socio-economic Characteristics in a Chinese Population Study. Journal of Happiness Studies, 2016, 17, 833-873.	3.2	121
71	Editorial: Some reflections on cost-effectiveness analysis. , 1998, 7, 1-7.		120
72	Genotype–covariate interaction effects and the heritability of adult body mass index. Nature Genetics, 2017, 49, 1174-1181.	21.4	119

#	Article	IF	CITATIONS
73	Anchoring and cognitive ability. Economics Letters, 2010, 107, 66-68.	1.9	115
74	Theory and Methods of Economic Evaluation of Health Care. Developments in Health Economics and Public Policy, 1996, , .	0.4	115
75	Willingness to pay for antihypertensive therapy — further results. Journal of Health Economics, 1993, 12, 95-108.	2.7	114
76	On the measurement of relative and absolute income-related health inequality. Social Science and Medicine, 2002, 55, 1923-1928.	3.8	114
77	Delayed Puberty in Girls With Cystic Fibrosis Despite Good Clinical Status. Pediatrics, 1997, 99, 29-34.	2.1	112
78	Limbic Justice—Amygdala Involvement in Immediate Rejection in the Ultimatum Game. PLoS Biology, 2011, 9, e1001054.	5.6	111
79	The Validity of QALYs. Medical Decision Making, 1997, 17, 21-32.	2.4	110
80	Is the valuation of a QALY gained independent of age? Some empirical evidence. Journal of Health Economics, 1997, 16, 589-599.	2.7	109
81	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169.	2.1	109
82	A comparison of individual and social time trade-off values for health states in the general population. Health Policy, 2006, 76, 359-370.	3.0	106
83	Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation. Southern Economic Journal, 1998, 65, 169-177.	2.1	106
84	Anticipated verbal feedback induces altruistic behavior. Evolution and Human Behavior, 2008, 29, 100-105.	2.2	105
85	Relationship Between Quality of Life Instruments, Health State Utilities, and Willingness to Pay in Patients with Asthma. Annals of Allergy, Asthma and Immunology, 1998, 80, 189-194.	1.0	103
86	The Relationship between Health-state Utilities and the SF-12 in a General Population. Medical Decision Making, 1999, 19, 128-140.	2.4	103
87	Does parametric fMRI analysis with SPM yield valid results?—An empirical study of 1484 rest datasets. NeuroImage, 2012, 61, 565-578.	4.2	103
88	Absolute Income, Relative Income, Income Inequality, and Mortality. Journal of Human Resources, 2004, 39, 228.	3.1	100
89	The Behavioral Genetics of Behavioral Anomalies. Management Science, 2012, 58, 21-34.	4.1	100
90	Characterizing QALYs by Risk Neutrality. Journal of Risk and Uncertainty, 1997, 15, 107-114.	1.5	99

#	Article	IF	CITATIONS
91	Molecular Genetics and Economics. Journal of Economic Perspectives, 2011, 25, 57-82.	5.9	99
92	Resource Utilization and Costs of Stroke Unit Care Integrated in a Care Continuum: A 1-Year Controlled, Prospective, Randomized Study in Elderly Patients. Stroke, 2000, 31, 2569-2577.	2.0	98
93	An Experimental Test of a Theoretical Foundation for Rating-scale Valuations. Medical Decision Making, 1997, 17, 208-216.	2.4	97
94	To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age. Journal of Risk and Uncertainty, 1996, 13, 163-174.	1.5	94
95	A Note on QALYs, Time Tradeoff, and Discounting. Medical Decision Making, 1994, 14, 188-193.	2.4	93
96	The value of private safety versus the value of public safety. Journal of Risk and Uncertainty, 1996, 13, 263-275.	1.5	92
97	Replicability and Robustness of Genome-Wide-Association Studies for Behavioral Traits. Psychological Science, 2014, 25, 1975-1986.	3.3	92
98	Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine. Medical Decision Making, 1999, 19, 371-377.	2.4	91
99	Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies. Pharmacoeconomics, 2003, 21, 39-48.	3.3	91
100	Intuition and Moral Decision-Making – The Effect of Time Pressure and Cognitive Load on Moral Judgment and Altruistic Behavior. PLoS ONE, 2016, 11, e0164012.	2.5	91
101	On the Value of Changes in Life Expectancy: Blips Versus Parametric Changes. Journal of Risk and Uncertainty, 1997, 15, 221-239.	1.5	90
102	The relationship between cost-effectiveness analysis and cost-benefit analysis. Social Science and Medicine, 1995, 41, 483-489.	3.8	89
103	No Association between Oxytocin Receptor (OXTR) Gene Polymorphisms and Experimentally Elicited Social Preferences. PLoS ONE, 2010, 5, e11153.	2.5	88
104	Higher cognitive ability is associated with lower entries in a p-beauty contest. Journal of Economic Behavior and Organization, 2009, 72, 171-175.	2.0	87
105	Crowdsourcing hypothesis tests: Making transparent how design choices shape research results Psychological Bulletin, 2020, 146, 451-479.	6.1	87
106	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	12.8	84
107	Willingness to Pay for Reductions in Angina Pectoris Attacks. Medical Decision Making, 1996, 16, 248-253.	2.4	83
108	Calibrating Hypothetical Willingness to Pay Responses. Journal of Risk and Uncertainty, 1999, 18, 21-32.	1.5	83

#	Article	IF	CITATIONS
109	Incorporating Future Costs in Medical Cost-Effectiveness Analysis. Medical Decision Making, 1997, 17, 382-389.	2.4	82
110	Molecular genetics and subjective well-being. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9692-9697.	7.1	82
111	The psychometric and empirical properties of measures of risk preferences. Journal of Risk and Uncertainty, 2017, 54, 203-237.	1.5	82
112	Income-related inequality in life-years and quality-adjusted life-years. Journal of Health Economics, 2000, 19, 1007-1026.	2.7	80
113	The Relationship between Genes, Psychological Traits, and Political Participation. American Journal of Political Science, 2014, 58, 888-903.	4.5	79
114	Meta-GWAS Accuracy and Power (MetaGAP) Calculator Shows that Hiding Heritability Is Partially Due to Imperfect Genetic Correlations across Studies. PLoS Genetics, 2017, 13, e1006495.	3.5	78
115	Conspicuous generosity. Journal of Public Economics, 2011, 95, 1131-1143.	4.3	77
116	Willingness to pay for reduced incontinence symptoms. BJU International, 1997, 80, 557-562.	2.5	74
117	The effect of fast and slow decisions on risk taking. Journal of Risk and Uncertainty, 2017, 54, 37-59.	1.5	73
118	Confidence interval estimation tasks and the economics of overconfidence. Journal of Economic Behavior and Organization, 2006, 61, 453-470.	2.0	72
119	Are boys discriminated in Swedish high schools?. Economics of Education Review, 2011, 30, 682-690.	1.4	72
120	Regional differences in health status in China: Population health-related quality of life results from the National Health Services Survey 2008. Health and Place, 2011, 17, 671-680.	3.3	72
121	The impact of hormone replacement therapy on quality of life and willingness to pay. BJOG: an International Journal of Obstetrics and Gynaecology, 1997, 104, 1191-1195.	2.3	71
122	An epigenome-wide association study meta-analysis of educational attainment. Molecular Psychiatry, 2017, 22, 1680-1690.	7.9	70
123	A note on the estimation of the equity-efficiency trade-off for QALYs. Journal of Health Economics, 1996, 15, 359-368.	2.7	68
124	Is There a Hold-up Problem?. Scandinavian Journal of Economics, 2004, 106, 475-494.	1.4	68
125	Urge Incontinence. Pharmacoeconomics, 1998, 14, 531-539.	3.3	67
126	The Genetic Origins of the Relationship between Psychological Traits and Social Trust. Twin Research and Human Genetics, 2012, 15, 21-33.	0.6	66

#	Article	IF	CITATIONS
127	Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Human Reproduction, 1998, 13, 2092-2097.	0.9	64
128	Linking Genes and Political Orientations: Testing the Cognitive Ability as Mediator Hypothesis. Political Psychology, 2015, 36, 649-665.	3.6	64
129	Deteriorating health status in Stockholm 1998–2002: results from repeated population surveys using the EQ-5D. Quality of Life Research, 2007, 16, 1547-1553.	3.1	63
130	Eliciting Willingness to Pay without Bias using Follow-up Certainty Statements: Comparisons between Probably/Definitely and a 10-point Certainty Scale. Environmental and Resource Economics, 2009, 43, 473-502.	3.2	63
131	Resource profile and user guide of the Polygenic Index Repository. Nature Human Behaviour, 2021, 5, 1744-1758.	12.0	63
132	Quality of life and the WTP for an increased life expectancy at an advanced age. Journal of Public Economics, 1997, 65, 219-228.	4.3	62
133	Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour. Nature Human Behaviour, 2021, 5, 1717-1730.	12.0	62
134	The costâ€effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Journal of Internal Medicine, 1993, 234, 317-323.	6.0	61
135	Are Healthy-years Equivalents an Improvement over Quality-adjusted Life Years?. Medical Decision Making, 1993, 13, 281-286.	2.4	61
136	The demand for health: results from new measures of health capital. European Journal of Political Economy, 1999, 15, 501-521.	1.8	59
137	The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25 000 subjects. Molecular Psychiatry, 2015, 20, 735-743.	7.9	59
138	Valuation of health changes with the contingent valuation method: A test of scope and question order effects. , 1996, 5, 531-541.		57
139	At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?. European Heart Journal, 2001, 22, 919-925.	2.2	57
140	Increasing socio-economic inequalities in life expectancy and QALYs in Sweden 1980-1997. Health Economics (United Kingdom), 2005, 14, 831-850.	1.7	57
141	A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility, 2017, 107, 1238-1245.	1.0	57
142	The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy, 1997, 41, 105-119.	3.0	56
143	Non-reciprocal altruism in dictator games. Economics Letters, 2000, 69, 137-142.	1.9	56
144	Heritability of Overconfidence. Journal of the European Economic Association, 2009, 7, 617-627.	3.5	55

9

#	Article	IF	CITATIONS
145	The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy, 1996, 36, 231-244.	3.0	54
146	New estimates of the demand for health: results based on a categorical health measure and Swedish micro data. Social Science and Medicine, 1999, 49, 1325-1332.	3.8	54
147	Time Preference for Health: A Test of Stationarity versus Decreasing Timing Aversion. Journal of Mathematical Psychology, 2001, 45, 265-282.	1.8	53
148	Pre-Birth Factors, Post-Birth Factors, and Voting: Evidence from Swedish Adoption Data. American Political Science Review, 2014, 108, 71-87.	3.7	53
149	#EEGManyLabs: Investigating the replicability of influential EEG experiments. Cortex, 2021, 144, 213-229.	2.4	52
150	Avoiding Double-Counting in Pharmacoeconomic Studies. Pharmacoeconomics, 1997, 11, 385-388.	3.3	51
151	Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy, 1998, 44, 123-134.	3.0	51
152	Methodology. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. European Journal of Public Health, 1999, 9, 211-217.	0.3	51
153	Cost-effectiveness analysis of hypertension treatment — A review of methodological issues. Health Policy, 1991, 19, 55-77.	3.0	49
154	A note on validating Wagstaff and van Doorslaer's health measure in the analysis of inequalities in health. Journal of Health Economics, 1999, 18, 117-124.	2.7	49
155	On the sources of the height–intelligence correlation: New insights from a bivariate ACE model with assortative mating. Behavior Genetics, 2011, 41, 242-252.	2.1	48
156	The Cost Effectiveness of Hypertension Treatment in Sweden. Pharmacoeconomics, 1995, 7, 242-250.	3.3	47
157	Is Altruism Paternalistic?. Economic Journal, 2007, 117, 761-781.	3.6	47
158	Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Results from the DIGAMI study. European Heart Journal, 2000, 21, 733-739.	2.2	46
159	Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma. Pharmacoeconomics, 2002, 20, 257-265.	3.3	45
160	Trust and Truth. Economic Journal, 2009, 119, 252-276.	3.6	45
161	Combined Oral Contraceptives and Sexual Function in Women—a Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4046-4053.	3.6	45
162	Time spent on waiting lists for medical care: an insurance approach. Journal of Health Economics, 1998, 17, 627-644.	2.7	44

#	Article	IF	CITATIONS
163	Predicting replication outcomes in the Many Labs 2 study. Journal of Economic Psychology, 2019, 75, 102117.	2.2	44
164	Cost-utility analysis from a societal perspective. Health Policy, 1997, 39, 241-253.	3.0	43
165	Communication: Content or relationship?. Journal of Economic Behavior and Organization, 2008, 65, 409-419.	2.0	43
166	Predicting the replicability of social science lab experiments. PLoS ONE, 2019, 14, e0225826.	2.5	43
167	The Costs of Treating Hypertension in Sweden. Scandinavian Journal of Primary Health Care, 1991, 9, 155-160.	1.5	42
168	Many Labs 5: Testing Pre-Data-Collection Peer Review as an Intervention to Increase Replicability. Advances in Methods and Practices in Psychological Science, 2020, 3, 309-331.	9.4	42
169	Costâ€benefit analysis of nonâ€pharmacological treatment of hypertension. Journal of Internal Medicine, 1991, 230, 307-312.	6.0	41
170	Cystic fibrosis mRNA expression in rat brain. NeuroReport, 1997, 8, 535-539.	1.2	41
171	A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and Sterility, 2011, 95, 152-157.	1.0	41
172	The Molecular Genetic Architecture of Self-Employment. PLoS ONE, 2013, 8, e60542.	2.5	41
173	The costs of treating hypertension — an analysis of different cut-off points. Health Policy, 1991, 18, 141-150.	3.0	40
174	A Review of Cost-Effectiveness Analyses of Hypertension Treatment. Pharmacoeconomics, 1992, 1, 250-264.	3.3	40
175	Patients' willingness to pay for autologous blood donation. Health Policy, 1997, 40, 1-12.	3.0	40
176	Cystic fibrosis through a female perspective: Psychosocial issues and information concerning puberty and motherhood. Patient Education and Counseling, 1998, 34, 115-123.	2.2	40
177	Probability Weighting and Utility Curvature in QALY-Based Decision Making. Journal of Mathematical Psychology, 1999, 43, 238-260.	1.8	40
178	Education and Social Trust: Testing a Causal Hypothesis Using the Discordant Twin Design. Political Psychology, 2017, 38, 515-531.	3.6	40
179	A health-economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension, 1992, 10, 1063???1070.	0.5	39
180	Willingness to pay for lipid lowering: a health production function approach. Applied Economics, 1993, 25, 1023-1031.	2.2	39

#	Article	IF	CITATIONS
181	Genetic and Environmental Influences on the Relationship between Flow Proneness, Locus of Control and Behavioral Inhibition. PLoS ONE, 2012, 7, e47958.	2.5	39
182	The cost effectiveness of lipid lowering in Swedish primary health care. Journal of Internal Medicine, 1996, 240, 23-29.	6.0	38
183	Use of contingent valuation to place a monetary value on pharmacy services: An overview and review of the literature. Clinical Therapeutics, 1999, 21, 1402-1417.	2.5	37
184	Do Life-Saving Regulations Save Lives?. Journal of Risk and Uncertainty, 2002, 24, 231-249.	1.5	37
185	Gender differences in social framing effects. Economics Letters, 2013, 118, 470-472.	1.9	37
186	Creative destruction in science. Organizational Behavior and Human Decision Processes, 2020, 161, 291-309.	2.5	36
187	Economic evaluation of lipid lowering — A feasibility test of the contingent valuation approach. Health Policy, 1992, 20, 309-320.	3.0	34
188	The intuitive cooperation hypothesis revisited: a meta-analytic examination of effect size and between-study heterogeneity. Journal of the Economic Science Association, 2020, 6, 26-42.	2.3	34
189	A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Medical Informatics = Medecine Et Informatique, 1991, 16, 355-362.	0.8	33
190	Hypothetical versus real willingness to pay: some experimental results. Applied Economics Letters, 1997, 4, 149-151.	1.8	33
191	A comparison of patient and social tariff values derived from the time trade-off method. , 1999, 8, 541-545.		33
192	The Impact of Age on the Cost - Effectiveness of Hypertension Treatment. Medical Decision Making, 1994, 14, 236-244.	2.4	32
193	A COMPUTER MODEL TO ANALYZE THE COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY. International Journal of Technology Assessment in Health Care, 1999, 15, 352-365.	0.5	32
194	Stated Preferences, Real Behaviour and Anchoring: Some Empirical Evidence. Environmental and Resource Economics, 1999, 13, 235-248.	3.2	32
195	Should we aggregate relative or absolute changes in QALYs?. Health Economics (United Kingdom), 2001, 10, 573-577.	1.7	32
196	Time is not money. Journal of Economic Behavior and Organization, 2009, 72, 96-102.	2.0	32
197	Distinct Loci in the <i>CHRNA5</i> / <i>CHRNA3</i> / <i>CHRNB4</i> Gene Cluster Are Associated With Onset of Regular Smoking. Genetic Epidemiology, 2013, 37, 846-859.	1.3	32
198	A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy, 1995, 33, 59-66.	3.0	31

#	Article	IF	CITATIONS
199	The economics of ageing: on the attitude of Swedish people to the distribution of health care resources between the young and the old. Health Policy, 1996, 37, 153-161.	3.0	31
200	Hypothetical versus real payments in Vickrey auctions. Economics Letters, 1997, 56, 177-180.	1.9	31
201	Perceptions and preferences of autologous blood donors. Transfusion, 1998, 38, 757-763.	1.6	31
202	The value of the change in health in Sweden 1980/81 to 1996/97. Health Economics (United Kingdom), 2003, 12, 637-654.	1.7	31
203	Sunk costs and fairness in incomplete information bargaining. Games and Economic Behavior, 2005, 50, 155-177.	0.8	30
204	fMRI data of mixed gambles from the Neuroimaging Analysis Replication and Prediction Study. Scientific Data, 2019, 6, 106.	5.3	30
205	On the Discounting of Gained life-Years in Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care, 1992, 8, 359-364.	0.5	29
206	A note on the relationship between ex ante and expected willingness to pay for health care. Social Science and Medicine, 1996, 42, 305-311.	3.8	29
207	The Effect of Changes in Treatment Patterns on Drug Expenditure. Pharmacoeconomics, 1998, 13, 127-134.	3.3	29
208	The costâ€effectiveness of a cardiovascular multipleâ€riskâ€factor intervention programme in treated hypertensive men. Journal of Internal Medicine, 1995, 237, 19-26.	6.0	28
209	The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation. Medical Care, 1998, 36, 1162-1173.	2.4	28
210	Theory and methods of economic evaluation of health care. Developments in Health Economics and Public Policy, 1996, 4, 1-245.	0.4	28
211	The Ranking Properties of Healthy-Years Equivalents and Quality-Adjusted Life-Years Under Certainty and Uncertainty. International Journal of Technology Assessment in Health Care, 1995, 11, 40-48.	0.5	27
212	Discrimination against students with foreign backgrounds: evidence from grading in Swedish public high schools. Education Economics, 2015, 23, 660-676.	1.1	27
213	Estimating the Impact of Education on Political Participation: Evidence from Monozygotic Twins in the United States, Denmark and Sweden. Political Behavior, 2016, 38, 579-601.	2.7	27
214	Does Gender Diversity Promote Nonconformity?. Management Science, 2017, 63, 1085-1096.	4.1	27
215	Is research in social psychology politically biased? Systematic empirical tests and a forecasting survey to address the controversy. Journal of Experimental Social Psychology, 2018, 79, 188-199.	2.2	27
216	Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?. SSRN Electronic Journal, 0, , .	0.4	27

#	Article	IF	CITATIONS
217	Economic Evaluation in Healthcare. Pharmacoeconomics, 1996, 10, 114-122.	3.3	26
218	An Experimental Investigation of Election Promises. Political Psychology, 2018, 39, 685-705.	3.6	26
219	Are women more generous than men? A meta-analysis. Journal of the Economic Science Association, 2021, 7, 1-18.	2.3	26
220	The discounting of lives saved in future generations—some empirical results. Health Economics (United Kingdom), 1996, 5, 329-332.	1.7	25
221	The co-twin methodology and returns to schooling — testing a critical assumption. Labour Economics, 2014, 26, 1-10.	1.7	25
222	Economic Evaluation of Drugs and its Potential Uses in Policy Making. Pharmacoeconomics, 1995, 8, 190-198.	3.3	24
223	Quality-adjusted life-years versus healthy-years equivalents — A comment. Journal of Health Economics, 1995, 14, 9-16.	2.7	23
224	Experimental Game Theory and Behavior Genetics. Annals of the New York Academy of Sciences, 2009, 1167, 66-75.	3.8	23
225	The Concept of Cost in the Economic Evaluation of Health Care: <i>A Theoretical Inquiry</i> . International Journal of Technology Assessment in Health Care, 1994, 10, 675-682.	0.5	22
226	Value for money? A contingent valuation study of the optimal size of the Swedish health care budget. Health Policy, 1995, 34, 135-143.	3.0	22
227	The heritability of moral standards for everyday dishonesty. Journal of Economic Behavior and Organization, 2013, 93, 363-366.	2.0	22
228	A creative destruction approach to replication: Implicit work and sex morality across cultures. Journal of Experimental Social Psychology, 2021, 93, 104060.	2.2	22
229	Consensus-based guidance for conducting and reporting multi-analyst studies. ELife, 2021, 10, .	6.0	22
230	Economic Evaluation of Hypertension Treatment. International Journal of Technology Assessment in Health Care, 1992, 8, 506-523.	0.5	21
231	The Australian Guidelines for Subsidisation of Pharmaceuticals. Pharmacoeconomics, 1992, 2, 355-362.	3.3	21
232	From Principle To Public Policy: Using Cost-Effectiveness Analysis. Health Affairs, 1994, 13, 206-214.	5.2	21
233	Are replication rates the same across academic fields? Community forecasts from the DARPA SCORE programme. Royal Society Open Science, 2020, 7, 200566.	2.4	21
234	Economic Evaluation of Drug Therapy. Pharmacoeconomics, 1992, 1, 325-337.	3.3	20

#	Article	IF	CITATIONS
235	Some further experimental results on hypothetical versus real willingness to pay. Applied Economics Letters, 1997, 4, 535-536.	1.8	20
236	Health State Utilities in Gastroesophageal Reflux Disease Patients with Heartburn: A Study in Germany and Sweden. Medical Decision Making, 2004, 24, 40-52.	2.4	20
237	The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy, 1994, 28, 1-13.	3.0	19
238	Consumption and Health. The BE Journal of Macroeconomics, 2006, 6, 1-30.	0.6	19
239	Hormonal Contraceptives Do Not Impact Economic Preferences: Evidence from a Randomized Trial. Management Science, 2018, 64, 4515-4532.	4.1	19
240	On the estimation of cost-effectiveness ratios. Health Policy, 1995, 31, 225-229.	3.0	18
241	Economic evaluation of osteoporosis prevention. Health Policy, 1993, 24, 103-124.	3.0	16
242	QALYs, HYEs and individual preferences— A graphical illustration. Social Science and Medicine, 1994, 39, 1623-1632.	3.8	16
243	Economic evaluation of health care and policymaking. Health Policy, 1995, 33, 179-190.	3.0	16
244	Personality Polygenes, Positive Affect, and Life Satisfaction. Twin Research and Human Genetics, 2016, 19, 407-417.	0.6	16
245	Cost-effectiveness analysis and capital costs. Social Science and Medicine, 1998, 46, 1183-1191.	3.8	15
246	An experimental test of question framing in health state utility assessment. Health Policy, 1998, 45, 187-193.	3.0	15
247	The digit ratio (2D:4D) and economic preferences: no robust associations in a sample of 330 women. Journal of the Economic Science Association, 2019, 5, 149-169.	2.3	15
248	2D:4D does not predict economic preferences: Evidence from a large, representative sample. Journal of Economic Behavior and Organization, 2021, 185, 390-401.	2.0	15
249	Cost-Effectiveness of Antihypertensive Treatment. Pharmacoeconomics, 1993, 3, 36-44.	3.3	14
250	Predicting replicability—Analysis of survey and prediction market data from large-scale forecasting projects. PLoS ONE, 2021, 16, e0248780.	2.5	14
251	The cost of screening for hypercholesterolaemia– results from a clinical trial in Swedish primary health care. Scandinavian Journal of Clinical and Laboratory Investigation, 1993, 53, 725-732.	1.2	13
252	The Impact of User Charges on the Consumption of Drugs. Pharmacoeconomics, 1996, 9, 478-483.	3.3	13

#	Article	IF	CITATIONS
253	Saving lives in the present versus saving lives in the futureis there a framing effect?. , 1997, 15, 167-176.		13
254	The Effect of Competition on Physical Activity: A Randomized Trial. B E Journal of Economic Analysis and Policy, 2010, 10, .	0.9	13
255	Drug Expenditure and New Drug Introductions. Pharmacoeconomics, 1993, 4, 215-225.	3.3	12
256	The costs and effects of two different lipid intervention programmes in primary health care. Journal of Internal Medicine, 1995, 237, 13-17.	6.0	12
257	A pilot test of using the veil of ignorance approach to estimate a social welfare function for income. Applied Economics Letters, 1995, 2, 400-402.	1.8	12
258	Incorporating quality of life changes into economic evaluations of health care: an overview. Health Policy, 1996, 36, 155-166.	3.0	12
259	The Psychometric and Empirical Properties of Measures of Risk Preferences. SSRN Electronic Journal, 2015, , .	0.4	12
260	Subliminal influence on generosity. Experimental Economics, 2017, 20, 531-555.	2.1	12
261	The contingent valuation method—appraising the appraisers. Health Economics (United Kingdom), 1993, 2, 357-359.	1.7	11
262	Contingent valuation with an open-ended follow-up question: a test of scope effects. , 1997, 6, 637-639.		11
263	The Contingent-valuation Method. Medical Decision Making, 1993, 13, 311-312.	2.4	10
264	A note on prevention versus cure. Health Policy, 1997, 41, 181-187.	3.0	10
265	On aggregating QALYs: a comment on Dolan. Journal of Health Economics, 1999, 18, 381-386.	2.7	10
266	Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Archives of Internal Medicine, 1994, 154, 2020-5.	3.8	10
267	Use of Misoprostol in the Elderly. Drugs and Aging, 1996, 8, 84-88.	2.7	9
268	The value of life extension and the marginal rate of time preference: a pilot study. Applied Economics Letters, 1997, 4, 53-55.	1.8	9
269	Polymorphic Expression of Multidrug Resistance mRNA in Lung Parenchyma of Nonpregnant and Pregnant Rats: A Comparison to Cystic Fibrosis mRNA Expression. Biochemical and Biophysical Research Communications, 1997, 239, 606-611.	2.1	9
270	Cost Benefit of Treating Hypertension. Clinical and Experimental Hypertension, 1999, 21, 987-997.	1.3	9

#	Article	IF	CITATIONS
271	Can monetary incentives increase organ donations?. Economics Letters, 2016, 142, 56-58.	1.9	8
272	A health-economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension, 1992, 10, 1063-70.	0.5	8
273	Do People Care About Social Context? Framing Effects in Dictator Games. SSRN Electronic Journal, 2012, , .	0.4	7
274	Using prediction markets to forecast research evaluations. Royal Society Open Science, 2015, 2, 150287.	2.4	7
275	2D:4D and Self-Employment: A Preregistered Replication Study in a Large General Population Sample. Entrepreneurship Theory and Practice, 2022, 46, 21-43.	10.2	7
276	Price Indices of Drugs and the Switching to New Drugs. Pharmacoeconomics, 1998, 13, 71-80.	3.3	6
277	Economics, Pharmaceuticals, and Pharmacoeconomics. Medical Decision Making, 1998, 18, S1-S3.	2.4	6
278	Does Impartial Deliberation Breed Fair Behavior?. Rationality and Society, 2005, 17, 116-136.	1.1	6
279	Generosity and Political Preferences. SSRN Electronic Journal, 0, , .	0.4	6
280	Cost-benefit analysis of lipid lowering therapy. European Heart Journal, 1997, 18, 165-166.	2.2	5
281	Cost-utility analysis and varying preferences for health. Health Policy, 1997, 41, 201-205.	3.0	5
282	The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. Journal of Human Hypertension, 1996, 10 Suppl 2, S23-6.	2.2	5
283	Qalys: A comment. Journal of Public Economics, 1995, 56, 327-328.	4.3	4
284	Bargaining over a Common Good with Private Information*. Scandinavian Journal of Economics, 2009, 111, 547-565.	1.4	4
285	Using prediction markets to predict the outcomes in the Defense Advanced Research Projects Agency's next-generation social science programme. Royal Society Open Science, 2021, 8, 181308.	2.4	4
286	Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Archives of Internal Medicine, 1994, 154, 2020-2025.	3.8	4
287	Valuation of health changes with the contingent valuation method: A test of scope and question order effects. Health Economics (United Kingdom), 1996, 5, 531-541.	1.7	2
288	Has the Cost-effectiveness of Misoprostol Been Underestimated?-Reply. Archives of Internal Medicine, 1995, 155, 1451.	3.8	1

#	Article	IF	CITATIONS
289	Guest Editors' Preface to the Special Symposium on Field Experiments. Scandinavian Journal of Economics, 2013, 115, 1-2.	1.4	1
290	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	1
291	The Expressed Preference Approach. Developments in Health Economics and Public Policy, 1996, , 75-100.	0.4	1
292	Cost Effectiveness and Allocation of Therapies in a Treating Population. Pharmacoeconomics, 1997, 11, 606-606.	3.3	0
293	The value of changes in health risks: a review. , 1998, , 101-120.		0
294	Eliciting Willingness to Pay Without Bias Using Follow-Up Certainty Statements: Comparisons Between Probably/Definitely and a 10-Point Certainty Scale. SSRN Electronic Journal, 0, , .	0.4	0
295	Sex hormones and economic decision making in the lab. , 2018, , 391-402.		0
296	POS0348â€GENETIC SUSCEPTIBILITY VARIANTS FOR RHEUMATOID ARTHRITIS ARE NOT ASSOCIATED WITH EA REMISSION; A MULTI-COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 403.1-404.	rly.9	0
297	Economic Evaluation and Policy Making. Developments in Health Economics and Public Policy, 1996, , 221-236.	0.4	0
298	Cost-Effectiveness Analysis. Developments in Health Economics and Public Policy, 1996, , 135-172.	0.4	0
299	Cost-Utility Analysis. Developments in Health Economics and Public Policy, 1996, , 173-220.	0.4	0
300	Datasets from a research project examining the role of politics in social psychological research. Scientific Data, 2018, 5, 180236.	5.3	0
301	The discounting of lives saved in future generations—some empirical results. Health Economics (United Kingdom), 1996, 5, 329-332.	1.7	0